medigraphic.com

2002, Number S1

<< Back Next >>

Arch Cardiol Mex 2002; 72 (S1)

Stratification of coronary risk

Martínez-Réding GJ

Language: Spanish
References: 14
Page: 130-134
PDF size: 56.01 Kb.


ABSTRACT

Coronary atheroselerosis constitutes the fifth leading cause of global disease burden and the leading cause in developed societies. Coronary artery disease is the leading cause of morbidity and mortality in the, United States, Western industrialized societies; in our country, it has become a real healt problem. Compelling epidemiologic and clinical data have demonstrated that elevated total cholesterol levels, high blood pressure, and diabetes mellitus correlate with increasing coronary artery disease mortality. Risk factors modification in the general public and persons at high risk offers the best opportunity for effectively reducing the prevalence of coronary heart disease.


REFERENCES

  1. Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in adults, National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel II). Circulation 1994; 89: 1329-1445.

  2. Tracy RP: Inflammation markers and coronary heart disease. Curr Opin Lipidoll 1999; 110: 435-441.

  3. Greenland P, Abrams J, Aurigemma GP: Prevention Conference V. Beyond secondary prevention: Identifying the high risk patient for primary prevention. Noninvasive tests of atherosclerotic burden. Circulation 2000; 101: e16-e20.

  4. Wood D, de Backer G, Faegerman O, Graham I, Mancia G, Pyrala K: Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second Joint Task Force of European and other societies on coronary Prevention. J Hypertens 1998: 16: 1407-1414.

  5. Doyle JT, Dawber TR, Kannel WB, Heslin AS, Kahn HA: Cigarette smoking and coronary heart disease: combined experience of the Albany and Framingham studies. N Engl J Med 1988; 266: 796-801.

  6. Sorlie PD, Kannel WB: A description of cigarette smoking cessation and resumption in the Framingham Study. Prev Med 1990; 19: 335-345.

  7. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statment for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100: 1481-1492.

  8. Dalageer-Pedersen S, Berg H, Falk E: Atherosclerosis and Acute Coronary Events. Am J Cardiol 1998; 82: 37T-40T.

  9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993; 269: 3015-3023.

  10. Lacoste L, Lam J, Hung J, Letchacovski G, Solymoss CH, Waters D: Hyperlipidemia and Coronary Disease. Correction of the Increased. Thrombogenic Potential with Cholesterol Reduction. Circulation 1995; 92: 3172-3177.

  11. Grundy S, Balady G, Criqui M, Fletcher G, Greenland P, Hiratzka L: Primary Prevention of Coronary Heart Disease: Guidance From Framingham. A Statement for Healthcare Professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876-1887.

  12. Wood D, Durrington P, Mc Innes G, Poulter N, Rees A, Wray A: Joint British reconditions on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2): S1-S29.

  13. D’ Agostino RB, Kannel WB, Belanger AJ, Sytkowski PA: Trends in CHD and risk factors at age 55-64 in the Framingham Study. Int J Epidemiol 1989; 18(Suppl 1): S67-S72).

  14. Wroblewski L, Cooke J: Phytoestrogens and Cardiovascular Health. J Am Coll Cardiol 2000; 35: 1403-1410.




2020     |     www.medigraphic.com